设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至[email protected]

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑(兼编辑部主任):

杨秋
副总编辑:魏永祥、张运、

罗毅、谭学瑞、唐来坤、

王喜艳

编辑部副主任:杨水霞
邮发代号:80-528
定价:18.00元
全年:216.00元
Email:[email protected]
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2019 年第 2 期 第 14 卷

帕拉米韦与奥司他韦治疗儿童流感病毒肺炎的成本-效果分析

Cost-effectiveness analysis of peramivir and oseltamivir in treatment of influenza virus pneumonia in children

作者:陈圣洁戴兰芬李丹丹王乐李成玲蒋春颖

英文作者:

单位:050031石家庄,河北省儿童医院药剂科(陈圣洁、李成玲),呼吸科(戴兰芬、李丹丹),儿科研究所(王乐);065500河北省廊坊市固安县人民医院医保科(蒋春颖)

英文单位:

关键词:流感病毒肺炎;帕拉米韦;奥司他韦;成本-效果分析

英文关键词:

  • 摘要:
  • 【摘要】

    【摘要】目的    分析帕拉米韦与奥司他韦治疗儿童流感病毒肺炎的成本及效果。方法    选取2017年2月至2018年2月河北省儿童医院收治的98例儿童流感病毒肺炎患者,按照随机数表法分为A组和B组,每组49例。A组采用帕拉米韦氯化钠注射液静脉滴注治疗,B组采用磷酸奥司他韦颗粒口服治疗,按照体质量给药。比较2组患儿的临床疗效、治疗后的症状体征改善时间和用药时间以及住院时间,计算用药成本,并比较2组不良反应的发生情况。结果    A组和B组治疗总有效率比较[91.8%(45/49)比85.7%(42/49)],差异无统计学意义(P=0.337)。A组患儿体温下降、体温恢复、咳嗽消失、肺部啰音消失时间以及用药时间、住院时间均明显短于对照组[(1.4±0.5)d比(2.5±0.6)d、(2.7±0.9)d比(4.8±1.4)d、(9.0±1.3)d比(11.5±1.8)d、(6.6±0.8)d比(10.8±1.8)d、(3.0±0.5)d比(4.5±1.1)d、(7.8±1.6)d比(12.8±1.9)d](均P<0.001)。A组用药成本明显高于B组[(686±128)元比(158±25)元](P<0.001)。A组和B组药物不良反应发生率比较,差异无统计学意义(P=0.766)。结论    帕拉米韦与奥司他韦治疗儿童流感病毒肺炎的疗效相当,且均具有较好的安全性。但与奥司他韦相比,帕拉米韦治疗可更加有效地促进临床症状体征改善,缩短用药及住院时间,但用药成本较高。


  • 【Abstract】Objective    To analyze the costs and effectiveness of peramivir and oseltamivir in the treatment of influenza virus pneumonia in children. Methods    Between February 2017 and February 2018, 98 children with influenza virus pneumonia were enrolled in Children′s Hospital of Hebei Province. They were randomly divided into group A and group B, with 49 cases in each group. The group A was treated with intravenous peramivir and the group B took oseltamivir. Clinical effectiveness, recovery time of symptoms and signs, medication duration and hospital stay time, cost of drugs and incidence of adverse reactions were analyzed. Results    There was no significant difference of the total effective rate between the group A and group B[91.8%(45/49) vs 85.7%(42/49)](P=0.337). Body temperature drop time, body temperature recovery time, cough disappearing time, lung rales disappearing time, medication duration and hospital stay time in the group A were significantly shorter than those in the group B[(1.4±0.5)d vs (2.5±0.6)d, (2.7±0.9)d vs (4.8±1.4)d, (9.0±1.3)d vs (11.5±1.8)d, (6.6±0.8)d vs (10.8±1.8)d, (3.0±0.5)d vs (4.5±1.1)d, (7.8±1.6)d vs (12.8±1.9)d](P<0.001). Cost of drugs in the group A was significantly higher than that in the group B[(686±128)yuan vs (158±25)yuan](P<0.001). Incidence of adverse reactions showed no significant difference between the two groups(P=0.766). Conclusions    Peramivir and oseltamivir show similar efficacy and good safety in the treatment of influenza virus pneumonia in children. Peramivir is effective in improving clinical symptoms and reducing lengths of medication and hospital stay, but the cost is relatively high.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: [email protected]
网址:www.chinamedicinej.com 京ICP备10041176号-1
本系统由北京博思汇文数字科技有限公司设计开发 技术服务电话:400-921-9838
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱[email protected]







安卓


苹果

关闭